Efficacy and Safety of Tyrosine Kinase 2 Inhibitor Deucravacitinib in Psoriasis : A Systematic Review and Drug-Response Meta Analysis of RCTs. JIMKI. Published online December 10, 2025:10. doi:10.53366/jimki.vi.961